Regarding the effect of redoxivir in the treatment of new coronary pneumonia, the research team of China and the United States disclosed very different clinical trial results.
On the evening of April 29th, Beijing time, the internationally renowned medical journal “The Lancet” published the clinical trial of the new coronary pneumonia antiviral drug Ridesivir by the Chinese team result. The results of the study showed that no statistically significant clinical benefit was observed in the combination of Radecivir with standard therapy compared with standard therapy.
Professor Cao Bin from the China-Japan Friendship Hospital and Capital Medical University, who was in charge of the study, said: “This trial found that despite the safety and tolerability of ridxivir Good, but there is no significant benefit compared to placebo. “
This is very different from the information disclosed by US research institutions.
April 29, U.S. local time, Gilead Sciences announced two good news:
One is that the clinical trial from the National Institutes of Health (NIH) has reached the main end point and the data is positive; the second is the publication of Gilead ’s open-label phase III clinical trial, which shows that patients who received 5 days of treatment The clinical improvement was similar to that of patients receiving 10 days of Radecivir therapy, with more than half of the patients achieving clinical recovery.
In response to the question that the conclusions of the clinical trials between China and the United States are quite different, Professor Cao Bin, the head of the clinical trial of Red West China responded to the surging news reporters: “This is Two different studies have different evaluation criteria. “
” The standard used at the beginning of the NIH in the United States was the same as ours, and it was later changed. “Cao Bin right The surging news reporter said.
Professor John Norrie of the University of Edinburgh (not involved in the study) said in the review: “Researchers must resist the temptation to lower the standard of evidence” In an insufficient degree of experiment, the lack of statistical significance means that the research results cannot be concluded. “
Behind the difference between the results of the Chinese and American trials
Behind the difference between the results of the Chinese and American trials
This study conducted by the Chinese team was the first to evaluate Randomized, double-blind, placebo-controlled clinical trial of the effectiveness of new coronary pneumonia (COVID-19) in severely ill adult patients. Test Yuhu